Amniox Medical said yesterday it landed a Federal Supply Schedule contract for its Neox and Clarix regenerative product lines with the US Military Health System.
The Neox wound allograft is designed for use as a wound covering for dermal ulcers and defects, while its Clarix regenerative matrix is indicated for use as a surgical covering, wrap or barrier during orthopedic surgery and soft tissue repair, Atlanta-based Amniox said.
Amniox said that the contract will serve all US Department of Defense institutions, and the company will partner exclusively with veteran-owned small business Alliant Healthcare to provide the products.
“We are pleased to increase the availability of our unique technologies for the nation’s Veterans and Active Duty Military patients and the clinicians who deliver care to them. Acknowledgement of the clinical benefits that our proprietary technology offers to patients continues to deepen among providers and payers, now including broad accessibility this very important patient population through this contract,” CEO Tom Dugan said in a prepared statement.
The contract has no maximum value and took effect April 15 and is in effect through July 31, 2020, an Amniox Medical spokesperson told MassDevice.com. The contract will cover the Department of Veterans Affairs, Indian Health, Bureau of Prisons, the NIH, HHS and US Public Health, according to the spokesperson.
Last April, Amniox touted a reimbursement win from Palmetto Medicare as well as a 2-year cryopreserved lifespan for its Neox Cord 1k as it attempts to position itself as a market leader in wound care.
The company said that Palmetto Medicare recently included Amniox’s Neox Cord 1k and Neox 100 would allografts in a new skin substitute reimbursement policy, growing the product reach to more than 70% of Medicare patients.
The policy shift will allow for skin substitute applications that are medically necessary and follow proper billing guidelines, the company said.
